Fig 1.
Flow chart of study selection process.
PRISMA flow chart of the selection process of SMT-treated FD. SMT = Si-Mo-Tang oral liquid, FD = functional dyspepsia.
Table 1.
Summary of the characteristics of the included studies.
Fig 2.
The risk of bias assessment with the Cochrane Collaboration tool.
(A)Risk of bias graph. (B)Risk of bias summary.
Fig 3.
Efficacy rate and publication bias of SMT-treated FD after subgroup of SMT alone or combine with WM versus placebo or WM and sensitivity analysis.
(A)Forest plot of comparison: the efficacy rate of symptoms. (B) Funnel plot of publication bias of the included studies. SMT = Si-Mo-Tang oral liquid, WM = western medicine, FD = functional dyspepsia.
Fig 4.
Forest plot of the efficacy rate of SMT-treated FD after subgroup analysis of the different kinds of control interventions among SMT versus WM.
SMT = Si-Mo-Tang oral liquid, WM = western medicine, FD = functional dyspepsia.
Fig 5.
Forest plot of the efficacy rate of SMT-treated FD after excluding poor quality studies.
SMT = Si-Mo-Tang oral liquid, WM = western medicine, FD = functional dyspepsia.
Fig 6.
Forest plot of relapse rate of SMT-treated FD between experimental and control group.
SMT = Si-Mo-Tang oral liquid, FD = functional dyspepsia.
Fig 7.
Forest plot of safety profile and adverse events of SMT-treated FD.
SMT = Si-Mo-Tang oral liquid, FD = functional dyspepsia.